Medpace Holdings, Inc. (MEDP) Enterprise Value (EV): $12.69B
The enterprise value (EV) for Medpace Holdings, Inc. (MEDP) is $12.69B as of Wednesday, June 17, 2026.
MEDP Enterprise Value (EV) Metrics
ENTERPRISE VALUE (EV)
$12.69B
MEDP Competitors' Enterprise Value (EV)
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $13.05B | $12.69B |
| Solventum Corporation (SOLV)vs › | $12.91B | $17.95B |
| The Cooper Companies, Inc. (COO)vs › | $12.69B | $16.66B |
| DaVita Inc. (DVA)vs › | $13.52B | $24.07B |
| Align Technology, Inc. (ALGN)vs › | $12.43B | $10.36B |
| Revvity, Inc. (RVTY)vs › | $10.91B | $13.59B |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | $40.43B |
| Baxter International Inc. (BAX)vs › | $10.29B | $17.84B |
| Hologic, Inc. (HOLX)vs › | $16.97B | $15.94B |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.78B | $12.95B |
Enterprise Value Calculation
Market Cap
$13.05B
Total Debt
$136.85M
Cash
$497.05M
Enterprise Value
$12.69B
EV-Based Valuation Multiples
Why use EV instead of Market Cap?
- EV accounts for debt - an acquirer must pay or assume it
- EV deducts cash - the acquirer effectively receives it
- EV enables fair comparison of companies with different capital structures
- EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral
Medpace Holdings, Inc. Enterprise Value (EV) Formula & Definition
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. Enterprise Value (EV) FAQ
- What is the enterprise value (EV) for Medpace Holdings, Inc. (MEDP)?
- The enterprise value (EV) for MEDP stock is $12.69B.
Related Metrics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle